» Articles » PMID: 11429269

Depletion of Glial Cell Line-derived Neurotrophic Factor in Substantia Nigra Neurons of Parkinson's Disease Brain

Overview
Date 2001 Jun 29
PMID 11429269
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

The distribution of nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) in substantia nigra pars compacta (SNc) of Parkinson's disease (PD) brains was investigated by immunofluorescence. Cases studied included four 69-77 year old neurologically normal male controls and four 72-79 year old male PD patients. Integrated optical densities (IODs) of immunofluorescence over individual neuromelanin-containing neurons and in areas of neuropil and the number of neurons on H & E stained adjacent sections were quantitated with the use of the BioQuant Image Analyzer. Data were statistically analyzed by ANOVA, including the unpaired two-tailed Student t-test and the Mann-Whitney test. The results showed 55.8% (P<0.0001) dropout of SNc neurons in PD brains compared to age-matched controls. Despite considerable neuronal dropout, immunofluorescent NTFs in the PD brains showed differential reductions that were consistent within the group as compared to age-matched controls: reductions were GDNF, 19.4%/neuron (P<0.0001), 20.2%/neuropil (P<0.0001); CNTF, 11.1%/neuron (P<0.0001), 9.4%/neuropil (P<0.0001); BDNF, 8.6%/neuron (P<0.0001), 2.5%/neuropil. NGF, NT-3 and NT-4 showed no significant differences within surviving neurons or neuropil. Since the depletion of GDNF both within surviving neurons and neuropil was twice as great as that of CNTF and BDNF and since the other NTFs showed no changes, GDNF, of the tested NTFs, is probably the most susceptible and the earliest to decrease in the surviving neurons of SNc. These observations suggest a role for decreased availability of GDNF in the process of SNc neurodegeneration in PD.

Citing Articles

Intracerebellar upregulation of Rheb(S16H) ameliorates motor dysfunction in mice with SCA2.

Kim S, Park J, Eo H, Lee G, Park S, Shin M Acta Pharmacol Sin. 2025; .

PMID: 40033054 DOI: 10.1038/s41401-025-01504-y.


The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease.

Nelke A, Garcia-Lopez S, Caso J, Pereira M Stem Cell Res Ther. 2024; 15(1):356.

PMID: 39385216 PMC: 11465761. DOI: 10.1186/s13287-024-03965-0.


Effects and Mechanisms of Exercise on Brain-Derived Neurotrophic Factor (BDNF) Levels and Clinical Outcomes in People with Parkinson's Disease: A Systematic Review and Meta-Analysis.

Kaagman D, van Wegen E, Cignetti N, Rothermel E, Vanbellingen T, Hirsch M Brain Sci. 2024; 14(3).

PMID: 38539583 PMC: 10968162. DOI: 10.3390/brainsci14030194.


Endogenous GDNF Is Unable to Halt Dopaminergic Injury Triggered by Microglial Activation.

Mendes-Oliveira J, Campos F, Ferreira S, Tome D, Fonseca C, Baltazar G Cells. 2024; 13(1).

PMID: 38201277 PMC: 10778367. DOI: 10.3390/cells13010074.


Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.

Chhabra P, Rishabh , Singla S, Choudhary S, Kohli S, Bansal N CNS Neurol Disord Drug Targets. 2023; 23(8):996-1014.

PMID: 37815179 DOI: 10.2174/0118715273258646230920074421.